Elizabeth B Lamont, Emily Stein, Paolo Tarantino, Sara M Tolaney, Corinne Ahlberg, Krishna Chinnathambu, Jiezhi Qi, Jackie Bilan, Ruthie Davi, Lisa Ensign
{"title":"Pooled clinical trial analyses evaluating outcomes of HER2-low vs HER2-0 expression in patients with metastatic breast cancer following chemotherapy.","authors":"Elizabeth B Lamont, Emily Stein, Paolo Tarantino, Sara M Tolaney, Corinne Ahlberg, Krishna Chinnathambu, Jiezhi Qi, Jackie Bilan, Ruthie Davi, Lisa Ensign","doi":"10.1007/s10549-024-07581-7","DOIUrl":"https://doi.org/10.1007/s10549-024-07581-7","url":null,"abstract":"<p><p>The therapeutic importance of subsetting patients with HER2-negative breast cancer according to their tumors' cellular HER2 expression (e.g., HER2-low vs. HER2-0) is relatively new, stemming from the dramatic results of the DESTINY-04 trial which established HER2-low expression as actionable. Most prior observational research of traditionally HER2-negative patients suggests that tumor behavior and biology do not vary according to HER2-low vs. HER2-0 expression, though some studies suggest otherwise. Here we studied this question in women with metastatic breast cancer (MBC) who were treated with standard single agent chemotherapy in the setting of clinical trials carried out in the pre-DESTINY-04 era. After pooling data from 142 female patients with MBC across historic clinical trials and categorizing them according to HER2 expression (i.e., HER2-0 or HER2-low), we evaluated associations between HER2 expression and the outcomes of both progression-free survival (PFS) and overall survival (OS) with both Kaplan-Meier and Cox proportional hazards methods. Studying data from an era when quantifying amounts of tumor HER2 expression in HER2-negative patients was neither standardized nor clinically actionable, we found no meaningful clinical differences in PFS or OS according to HER2-low vs. HER2-0 status, supporting prior findings of no biologic differences.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142871407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Katherine Leggat-Barr, Douglas Yee, Erin Duralde, Caroline Hodge, Virginia Borges, Molly Baxter, Jessica Valdez, Tamandra Morgan, Judy Garber, Laura Esserman
{"title":"Correction: A roadmap to reduce the incidence and mortality of breast cancer by rethinking our approach to women's health.","authors":"Katherine Leggat-Barr, Douglas Yee, Erin Duralde, Caroline Hodge, Virginia Borges, Molly Baxter, Jessica Valdez, Tamandra Morgan, Judy Garber, Laura Esserman","doi":"10.1007/s10549-024-07572-8","DOIUrl":"https://doi.org/10.1007/s10549-024-07572-8","url":null,"abstract":"","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863058","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Luciana Berlanga, Vanesa Lotersztein, Eliseo I Aranda, Roxana Cerretini
{"title":"Contribution of large genomic rearrangements in BRCA1/2 genes and CHEK2 1100delC allele variant to the development of breast/ovarian cancer in Argentinian population.","authors":"Luciana Berlanga, Vanesa Lotersztein, Eliseo I Aranda, Roxana Cerretini","doi":"10.1007/s10549-024-07576-4","DOIUrl":"https://doi.org/10.1007/s10549-024-07576-4","url":null,"abstract":"<p><strong>Purpose: </strong>Among women in Argentina, the most common cancer is breast cancer (BC) with 21,631 new cases and 6436 deaths per year. The ovarian cancer (OC) is fifteenth in frequency. The contribution of cancer-related large genomic rearrangements (LGRs) of the BRCA1/BRCA2 genes and the 1100delC allelic variant in the CHEK2 gene has not yet been widely studied in our population.</p><p><strong>Methods: </strong>LGRs in the BRCA1/BRCA2 genes and the CHEK2 1100delC variant were analyzed using the MLPA technique in 85 unselected Argentinian BC/OC patients.</p><p><strong>Results: </strong>A pathogenic genetic variant (PV) was found in eleven out of 85 (12,9%) patients, 10 were LGRs in the BRCA1 gene, 9 deletions and one duplication and one the CHEK2 1100delC. Large deletions of exons 1-2 and 15 in BRCA1 gene were recurrent anomalies in our series.</p><p><strong>Conclusions: </strong>LGRs in the BRCA1 gene contributed significantly to the burden of PVs responsible for the development of BC and OC in our study population. On the other hand, the 1100delC variant in CHEK2 was observed at a very low frequency in our series formed mainly by the Spanish, Italian and Amerindian ethnic groups.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142863055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Laura Suman, Elisa D'Ascoli, Catherine Depretto, Alessandro Berenghi, Claudia De Berardinis, Gianmarco Della Pepa, Giovanni Irmici, Daniela Ballerini, Alice Bonanomi, Eleonora Ancona, Gianfranco Paride Scaperrotta
{"title":"Diagnostic performance of MRI-guided vacuum-assisted breast biopsy (VABB): an essential but still underused technique.","authors":"Laura Suman, Elisa D'Ascoli, Catherine Depretto, Alessandro Berenghi, Claudia De Berardinis, Gianmarco Della Pepa, Giovanni Irmici, Daniela Ballerini, Alice Bonanomi, Eleonora Ancona, Gianfranco Paride Scaperrotta","doi":"10.1007/s10549-024-07579-1","DOIUrl":"https://doi.org/10.1007/s10549-024-07579-1","url":null,"abstract":"<p><strong>Background: </strong>Magnetic resonance imaging (MRI)-guided vacuum-assisted breast biopsy (VABB) is an increasingly requested procedure, but it implies training and experience both in its execution and in determining radiological-pathological concordance and is therefore performed in dedicated breast centers. The purpose of this study is to evaluate the diagnostic performance of MRI-guided vacuum-assisted biopsy and to determine the upgrade rate after surgery or follow-up.</p><p><strong>Methods: </strong>We retrospectively evaluated all consecutive patients with suspicious MRI findings without corresponding mammographic and ultrasonographic findings who underwent MRI-guided vacuum-assisted breast biopsy (VABB) at our Institution from November 2020 to March 2023. We determined the sensitivity (SE), specificity (SP), positive predictive value (PPV), negative predictive value (NPV) and accuracy of the procedure; we also assessed upgrade rate to malignancies using surgery or at least 1-year negative follow-up as reference standard. Fisher's exact test was used to evaluate the correlation between enhancement size and type (mass/non-mass) and histological outcomes.</p><p><strong>Results: </strong>A total of 121 patients with 122 suspicious breast lesions have been included. 29.5% (n = 36) of these lesions were classified as malignant (B5), 23% (n = 28) were lesions with uncertain malignant potential (B3 lesions), and 47.5% (n =58) were benign (B2). Among B5 lesions, 47.22% (n =17) were ductal carcinomas in situ (DCIS) and 52.77% (n = 19) were invasive carcinomas. Among patients with already diagnosed breast cancer (n = 36), MRI-guided VABB identified additional foci of disease in 36.1% (n = 13) of the cases, specifically 10 foci on the same breast and 3 in the contralateral breast. Accuracy of MRI-guided VABB was 96.7%, SE was 90%, SP was 100%, PPV was 100%, and NPV was 95.3%. 4 benign lesions (B2 and B3) were upgraded to B5 lesions after surgery or follow-up; the upgrade rate to malignancies was 3.28%. Fisher's exact test showed a significant association between enhancement size and histological outcomes (OR = 2.38, p = 0.046), while enhancement type was not significantly correlated (OR = 0.88, p = 0.841). No major complications have been reported.</p><p><strong>Conclusions: </strong>MRI-guided VABB has proven to be a mini-invasive, safe, and accurate procedure for the diagnostic work-up of suspected breast lesions, which can help in the management of patients aiding in the correct surgical decisional process.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Syed Mahfuz Al Hasan, Kayode A Matthew, Adetunji T Toriola
{"title":"Education and mammographic breast density.","authors":"Syed Mahfuz Al Hasan, Kayode A Matthew, Adetunji T Toriola","doi":"10.1007/s10549-024-07575-5","DOIUrl":"https://doi.org/10.1007/s10549-024-07575-5","url":null,"abstract":"<p><strong>Purpose: </strong>There are conflicting reports on the associations of education with mammographic breast density (MBD). To address this, we investigated the associations of education with MBD and additionally determined if and to what extent this association is mediated by known confounders such as age and adiposity.</p><p><strong>Methods: </strong>Women (n = 1155) were recruited during their annual screening mammogram at the Joanne Knight Breast Health Center at Washington University School of Medicine in St. Louis, MO. We assessed MBD using volumetric percent density (VPD; Volpara 1.5; Volpara Health<sup>®</sup>). We performed generalized linear modeling adjusted for potential confounders to estimate the differences in VPD by education level and evaluated whether associations differ by race and menopausal status. We also performed mediation analysis using PROCESS macro version 4.3. VPD was log-transformed, and back-transformed values are reported.</p><p><strong>Results: </strong>Women with college (n = 401) and postgraduate education (n = 396) had higher VPD (7.21% [95% CI 6.87-7.59] and 7.18% [95% CI 6.82-7.53], respectively) compared to women (n = 358) with below college education (6.62% [95% CI 6.27-7.00]; p = 0.051) in analysis adjusted for age, body mass index (BMI) and other confounders. However, the association attenuated when the analysis was adjusted for body fat% instead of BMI (college graduate: 7.26% [95% CI 6.92-7.62]; postgraduate: 7.19% [95% CI 6.85-7.55] vs. below college: 6.78% [95% CI 6.41-7.16]; p = 0.156). Body fat% and BMI mediated 71% and 64% of the association between education and VPD, respectively in premenopausal women, but not in postmenopausal women. Associations did not differ by race.</p><p><strong>Conclusion: </strong>Education was not associated with VPD after adjusting for adiposity. Adiposity mostly mediated the association between education and VPD, particularly among premenopausal women with body fat% a slightly more robust capture of adiposity than BMI.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142833895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Oncologic and cosmetic outcomes of oncoplastic breast-conserving surgery after neoadjuvant systemic therapy: systematic review and meta-analysis.","authors":"Goran A Ahmed, Daniel H Baron, Amit Agrawal","doi":"10.1007/s10549-024-07566-6","DOIUrl":"https://doi.org/10.1007/s10549-024-07566-6","url":null,"abstract":"<p><strong>Purpose: </strong>Oncoplastic breast-conserving surgery (OBCS) prevents compromise of breast aesthetics following large breast cancer excisions. This systematic review was conducted to investigate the outcomes (oncologic, surgical, cosmetic) of OBCS versus standard breast-conserving surgery (SBCS) and mastectomy post-neo-adjuvant systemic therapy.</p><p><strong>Methods: </strong>Ovid, Web of Science, Cochrane, ClinicalTrials.gov databases were searched up to 24/08/2024. English language peer-reviewed RCTs or observational/cohort studies with ≥ 18-year-old women treated for breast cancer with neoadjuvant chemotherapy (NACT) and/or hormonal therapy comparing OBCS to SBCS and/or mastectomy were included. Of 6794 articles, 32 underwent full-text assessment and eleven met the inclusion criteria. The review was conducted using PRISMA guidelines. Two reviewers independently extracted data and assessed risk of bias (Newcastle-Ottowa Scale). Meta-analysis using a random-effects model were performed where data allowed.</p><p><strong>Results: </strong>Eleven cohort studies (n = 4594) included OBCS (n = 912), SBCS (n = 1122) and mastectomy (n = 2560) after NACT. Post-NACT tumour size was 20(9-44) mm, 13(0-23)mm [SMD 0.62, 95%CI(-0.24,1.48), p = 0.16] and 20(10-31)mm [SMD 0.05, 95%CI(-0.53,0.63), p = 0.86] in the OBCS, SBCS and mastectomy groups respectively. The margin re-excision rate was significantly lower in OBCS than in SBCS [2.9%(0-11.1%) vs. 6.1%(0-18.5%); OR 0.35, 95%CI(0.15,0.80), p = 0.01]. All other oncologic outcomes, including positive margin rate, and overall survival, were not statistically different between the groups. Cosmetic outcomes and patient-reported outcome measures were marginally in favour of OBCS [OBCS 50-66% vs SBCS 37.6-55% very satisfied].</p><p><strong>Conclusion: </strong>OBCS after NACT appears oncologically safe and a potential alternative in patients with partial or poor tumour response to NACT. Further studies are required, directly comparing well-matched OBCS with SBCS and mastectomy patients after NACT.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142823884","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Naima Tariq, Shefali Dani, Purnima Makhija, Madhuri V Warren
{"title":"Breast hamartomas associated with epithelial atypia and malignancy: are there specific clinical, radiological or pathological features that identify at risk patients?","authors":"Naima Tariq, Shefali Dani, Purnima Makhija, Madhuri V Warren","doi":"10.1007/s10549-024-07577-3","DOIUrl":"https://doi.org/10.1007/s10549-024-07577-3","url":null,"abstract":"<p><strong>Purpose: </strong>Breast hamartomas are rarely associated with epithelial atypia or malignancy. Since the introduction of digital mammography in the UK from 2008, hamartoma detection has increased. The aim of this study was to identify if there are characteristic clinical, radiological or histological features that distinguish hamartomas with intralesional atypia/malignancy (complex hamartomas, CH) or ipsilateral/contralateral atypia/malignancy (non-CH) from those without atypia/malignancy at diagnosis (other benign hamartomas, BH).</p><p><strong>Methods: </strong>We performed a retrospective single-institution review of 450 hamartomas reported between 2010 and 2023. Anonymised H&E sections and imaging of CH and non-CH were reviewed to identify distinguishing features.</p><p><strong>Results: </strong>13,441 benign breast lesions were biopsied/resected between 2010 and 2023 including 450 hamartomas (3.3%), 19 of which (4.2%) were associated with atypia or malignancy. 14 were analysed further (7 CH; 7 non-CH). The mean age of CH plus non-CH patients was significantly higher than patients with BH (47.5 vs. 40.6 years; p = 0.03). The mean size of CH was greater than non-CH (32.1 mm vs.17.6 mm; p = 0.06). There was a statistically significantly higher incidence of atypical/malignant lobular lesions (ALH/LCIS/ILC) in CH vs. non-CH (42.9% vs 0%; p = 0.05). MRI was performed in 2 CH and 3 non-CH; in all 5 the associated malignancy was detected. There was no significant difference between the CH and non-CH group in ultrasound/mammographic features, other hamartoma histological features or other associated benign breast changes.</p><p><strong>Conclusions: </strong>Ultrasound/mammogram are not sufficiently sensitive to identify hamartomas with associated atypia/malignancy. Certain hamartoma features may preferentially be associated with atypia/malignancy and which merit further radiological and/or detailed histological investigation.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142811890","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Gudbjörg Sigurjonsdottir, Tommaso De Marchi, Anna Ehinger, Johan Hartman, Susann Ullén, Karin Leandersson, Ana Bosch, Johan Staaf, Fredrika Killander, Emma Niméus
{"title":"Evaluation of alternative prognostic thresholds for SP142 and 22C3 immunohistochemical PD-L1 expression in triple-negative breast cancer: results from a population-based cohort.","authors":"Gudbjörg Sigurjonsdottir, Tommaso De Marchi, Anna Ehinger, Johan Hartman, Susann Ullén, Karin Leandersson, Ana Bosch, Johan Staaf, Fredrika Killander, Emma Niméus","doi":"10.1007/s10549-024-07561-x","DOIUrl":"https://doi.org/10.1007/s10549-024-07561-x","url":null,"abstract":"<p><strong>Background: </strong>Immune checkpoint inhibitors are now a part of the treatment arsenal for triple-negative breast cancer (TNBC) but refinement of PD-L1 as a prognostic and predictive biomarker is a clinical priority. We aimed to evaluate the relevance of novel PD-L1 immunohistochemical (IHC) thresholds in TNBC with regard to PD-L1 gene expression, prognostic value, tumor infiltrating lymphocytes (TILs), and TNBC molecular subtypes.</p><p><strong>Material & methods: </strong>PD-L1 was scored in a tissue microarray with the SP142 (immune cell (IC) score) and the 22C3 (combined positive score; CPS) IHC assays and TIL abundance evaluated in whole slides in a population-based cohort of 237 early-stage TNBC patients. Survival analysis was performed and RNA sequencing data employed for molecular profiling.</p><p><strong>Results: </strong>As expected, PD-L1 positivity (IC ≥ 1% and/or CPS ≥ 1) was significantly associated with better prognosis compared to zero PD-L1 expression. Importantly however, also patients with intermediate expression (IC > 0%, < 1%; CPS > 0, < 1) showed a trend toward improved outcome. Tumors with intermediate PD-L1 IHC expression also had intermediate PD-L1 (CD274) gene expression (mRNA). Patients who were both low in TILs (< 30%) and PD-L1 (IC < 1%; CPS < 1) tended to have the poorest prognosis. PD-L1 positive tumors clustered significantly more often as Immunomodulatory-high and Basal-Like 1-high TNBC molecular subtypes and were enriched in immune response and cell cycle/proliferation signaling pathways. PD-L1-zero tumors on the other hand were enriched in cell growth, differentiation, and metastatic potential pathways and clustered more prevalently as Luminal-Androgen-Receptor-high and Mesenchymal-high. PD-L1-intermediate tumors categorized with neither PD-L1-positive nor PD-L1-zero tumors on the hierarchical clustering level, consigning them as a unique subgroup.</p><p><strong>Conclusion: </strong>With both SP142 and 22C3, we identified an intermediate IHC PD-L1 group within TNBCs that was supported on the molecular level. Any PD-L1 IHC expression, even though it is < 1, tended to have positive prognostic impact. We suggest that the generally accepted threshold of PD-L1 IHC positivity in TNBC should be investigated further. The Swedish Cancerome Analysis Network - Breast (SCAN-B) study was retrospectively registered 2nd Dec 2014 at ClinicalTrials.gov; ID NCT02306096.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Meng Yue, Jianing Zhao, Si Wu, Lijing Cai, Xinran Wang, Ying Jia, Xiaoxiao Wang, Yongjun Wang, Yueping Liu
{"title":"Establishment of multiple machine learning prognostic model for gene differences between primary tumors and lymph nodes in luminal breast cancer.","authors":"Meng Yue, Jianing Zhao, Si Wu, Lijing Cai, Xinran Wang, Ying Jia, Xiaoxiao Wang, Yongjun Wang, Yueping Liu","doi":"10.1007/s10549-024-07574-6","DOIUrl":"https://doi.org/10.1007/s10549-024-07574-6","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to explore the correlation between primary tumors (PT) and paired metastatic lymph nodes (LN) and to develop a predictive model to provide evidence for forecasting patient prognoses.</p><p><strong>Methods: </strong>We obtained single-cell and bulk transcriptome data from the Gene Expression Omnibus database. Furthermore, mRNA transcriptomic data, encompassing 112 normal tissues and 1066 breast cancer samples, along with survival, clinical, and mutation information for breast cancer patients, were acquired from The Cancer Genome Atlas (TCGA). Employing a machine learning integration framework incorporating ten distinct algorithms, we developed and validated a prognostic model.</p><p><strong>Results: </strong>We constructed a prognostic model named Lymph Node Metastasis-Related Scores (LMRS) using 26 differentially expressed genes trained on eight TCGA datasets. Across validation sets, the model demonstrated a high C-index, signifying its stability and effectiveness, outperforming 64 models from other studies. Notably, cytolytic activity and T cell co-stimulation were downregulated in the high LMRS group, alongside a downregulation of immune cells, including B cells, CD8 + T cells, iDCs, and TILs. Similarly, most immune checkpoints exhibited a decreasing trend with high LMRS expression. Finally, we selected the hub biomarkers PGK1 and HSP90 for pathological verification. Results indicated higher expression levels in PT and LN compared to normal and benign tumors, with higher expression levels in LN than in PT.</p><p><strong>Conclusion: </strong>This comprehensive analysis sheds light on gene expression differences between PT and LN in breast cancer, culminating in the development of a multiple-gene prognostic model with high clinical accuracy for prognosis prediction.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
K-H Yoon, S-H Ahn, H-C Shin, H W Koh, J K-H Park, Y Myung, J H Jeong, C Y Heo, E-K Kim
{"title":"Oncoplastic breast reconstruction with single-port laparoscopically harvested omental flap: insights from a ten-year tertiary center experience.","authors":"K-H Yoon, S-H Ahn, H-C Shin, H W Koh, J K-H Park, Y Myung, J H Jeong, C Y Heo, E-K Kim","doi":"10.1007/s10549-024-07571-9","DOIUrl":"https://doi.org/10.1007/s10549-024-07571-9","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the 10-year functional and oncological outcomes of single-port laparoscopically harvested omental flap (SLOF) for immediate breast reconstruction after breast cancer surgery. The technical feasibility and oncologic safety of breast reconstruction using a laparoscopically harvested omental flap remain controversial.</p><p><strong>Methods: </strong>We examined 236 patients with breast cancer (including 2 patients with malignant phyllodes tumors) who underwent nipple-sparing mastectomy or breast-conserving surgery followed by immediate SLOF reconstruction between February 2015 and March 2024 at our institution. Short- and long-term outcomes were assessed. Cosmetic outcomes were evaluated using a three-panel assessment and the Seoul Breast Esthetic Scoring Tool and compared with those of a matched cohort of patients who underwent deep inferior epigastric perforator (DIEP) flap breast reconstruction.</p><p><strong>Results: </strong>The rate of clinically significant complications of Clavien-Dindo grade IIIa or greater was 3.8% (9/236). Two patients with flap failure required flap removal and conversion to other reconstruction procedures. The cosmetic satisfaction rates were 82.5% and 76.4% in the SLOF and DIEP groups, respectively (P = 0.467). Over a median 59-month follow-up, the local, regional, and systemic recurrence rates were 3%, 2.1%, and 3%, respectively. All patients underwent annual screening for gastric cancer via esophagogastroduodenoscopy, and there were no cases of delayed flap removal due to gastrectomy.</p><p><strong>Conclusions: </strong>Oncoplastic breast reconstruction using SLOF is safe and feasible. The natural contour and texture of the reconstructed breast and the nearly invisible scar at the abdominal single-port incision provide excellent cosmetic outcomes that are superior to those of other reconstruction methods.</p>","PeriodicalId":9133,"journal":{"name":"Breast Cancer Research and Treatment","volume":" ","pages":""},"PeriodicalIF":3.0,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142799339","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}